Press Releases

The U.S. Food and Drug Administration Grants Orphan Drug Designation to ACER-001 for the Potential Treatment of Maple Syrup Urine Disease In August 2014, Acer Therapeutics Inc., a pharmaceutical company developing therapies for serious rare diseases with significant unmet medical need, was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) to […]

Acer Therapeutics Licenses Exclusive Worldwide Rights from Baylor College of Medicine for Development of Sodium Phenylbutyrate for Maple Syrup Urine Disease In April 2014, Acer Therapeutics Inc. entered into an exclusive worldwide license agreement with Baylor College of Medicine to develop and commercialize formulations and prodrugs of sodium phenylbutyrate for the treatment of Maple Syrup […]